LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Secreted Proteins Prepare Breast Cancer Cells for Metastasis

By LabMedica International staff writers
Posted on 21 Apr 2015
Image: Two adjacent sections of a mouse breast tumor. The tissue at left was stained so that normal blood vessels can be seen (black arrow); extending from these vessels are blood filled channels (green arrows). On the right, the tissue was stained for a fluorescent protein expressed by the tumor cells. Here it is seen that blood-filled channels were actually formed by tumor cells in a process known as vascular mimicry (Photo courtesy of Cold Spring Harbor Laboratory).
Image: Two adjacent sections of a mouse breast tumor. The tissue at left was stained so that normal blood vessels can be seen (black arrow); extending from these vessels are blood filled channels (green arrows). On the right, the tissue was stained for a fluorescent protein expressed by the tumor cells. Here it is seen that blood-filled channels were actually formed by tumor cells in a process known as vascular mimicry (Photo courtesy of Cold Spring Harbor Laboratory).
Two genes that code for secreted proteins have been found to be responsible for the development of vascular mimicry—imitation blood vessels—by tumor cells and for preparing some tumor cell clones to spread away from the site of the primary tumor.

Investigators at Cold Spring Harbor Laboratory (NY, USA) and colleagues at the University of Cambridge (United Kingdom) studied the two genes, SERPINE2 (serpin peptidase inhibitor, clade E) and SLPI (secretory leukocyte peptidase inhibitor), in a polyclonal mouse breast tumor model.

The SERPINE 2 gene encodes a member of the serpin family of proteins, a group of proteins that inhibit serine proteases. Thrombin, urokinase, plasmin, and trypsin are among the proteases that this family member can inhibit. This gene is a susceptibility gene for chronic obstructive pulmonary disease and for emphysema. The SLPI gene encodes a secreted inhibitor which protects epithelial tissues from serine proteases. It is found in various secretions including seminal plasma, cervical mucus, and bronchial secretions, and has affinity for trypsin, leukocyte elastase, and cathepsin G. Its inhibitory effect contributes to the immune response by protecting epithelial surfaces from attack by endogenous proteolytic enzymes; the protein is also thought to have broad-spectrum antibiotic activity.

The investigators found that breast tumors in their mouse model comprised distinct clones whose component cells specialized in various functions such as dominating the primary tumor, contributing to metastatic populations, or showing tropism for entering the lymphatic or vasculature systems. The investigators were able to correlate these stable properties with distinct gene expression profiles. Those clones that efficiently entered the vasculature expressed the two secreted proteins, Serpine2 and Slpi, which were necessary and sufficient to program these cells for vascular mimicry. The data, which was published in the April 8, 2015, online edition of the journal Nature, indicated that these proteins not only drove the formation of extravascular networks but also ensured their perfusion by acting as anticoagulants.

The investigators proposed that vascular mimicry supported the ability of some breast tumor cells to contribute to distant metastases while simultaneously satisfying a critical need of the primary tumor to be fed by the vasculature. Enforced expression of SERPINE2 and SLPI in human breast cancer cell lines also programmed them for vascular mimicry, and SERPINE2 and SLPI were overexpressed preferentially in human patients that had lung-metastatic relapse. Thus, these two secreted proteins, and the phenotype they promote, may be broadly relevant as drivers of metastatic progression in human cancer.

"It is very neat to watch and see cells evolve to have these capacities," said senior author Dr. Simon Knott, research professor at Cold Spring Harbor Laboratory. "But on the other hand it is really scary to think that these cells are sitting there in people doing this. Targeting them might provide therapeutic benefits, but we are not sure yet."

Related Links:

Cold Spring Harbor Laboratory
University of Cambridge


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Rapid Test Reader
DIA5000

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
PURITAN MEDICAL